A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus

13 Pág.

Detalles Bibliográficos
Autores: Gonzalez-Valdivieso, Juan, Borrego, Belén, Girotti, Alessandra, Moreno, Sandra, Brun Torres, Alejandro, Bermejo-Martin, Jesús, Arias, F. Javier
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2020
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/340799
Acceso en línea:http://hdl.handle.net/10261/340799
https://api.elsevier.com/content/abstract/scopus_id/85084699015
Access Level:acceso abierto
Palabra clave:DNA vaccines
Rift Valley fever virus
Elastin-like recombinamers (ELRs)
In vivo immunogenicity
Vaccine technologies
id ES_c3e1b554c8340edb7febfdb0383331aa
oai_identifier_str oai:digital.csic.es:10261/340799
network_acronym_str ES
network_name_str España
repository_id_str
spelling A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever VirusGonzalez-Valdivieso, JuanBorrego, BelénGirotti, AlessandraMoreno, SandraBrun Torres, AlejandroBermejo-Martin, JesúsArias, F. JavierDNA vaccinesRift Valley fever virusElastin-like recombinamers (ELRs)In vivo immunogenicityVaccine technologies13 Pág.This work analyzes the immunogenicity of six genetically engineered constructs based on elastin-like recombinamers (ELRs) fused to the Gn glycoprotein from Rift Valley fever virus (RVFV). Upon transfection, all constructs showed no effect on cell viability. While fusion constructs including ELR blocks containing hydrophobic amino acids (alanine or isoleucine) did not increase the expression of viral Gn in eukaryotic cells, glutamic acid- or valine-rich fusion proteins showed enhanced expression levels compared with the constructs encoding the viral antigen alone. However, in vivo DNA plasmid immunization assays determined that the more hydrophobic constructs reduced viremia levels after RVFV challenge to a higher extent than glutamic- or valine-rich encoding plasmids and were better inducers of cellular immunity as judged by in vitro restimulation experiments. Although the Gn-ELR fusion constructs did not surpass the protective efficacy of a plasmid vaccine expressing nonfused Gn, our results warrant further experiments directed to take advantage of the immunomodulatory potential of ELR biomaterials for improving vaccines against infectious diseases.The authors are grateful for financial support from the European Social Fund (ESF) and the European Regional Development Fund (ERDF), as well as funding from the EU (H2020-NMP-2014-646075), the MICIUN (DTS19/00162, MAT2016-79435-R, MAT2016-78903-R and AGL2017-82336-R), the Comunidad de Madrid (project S2018/BAA-4370) the JCyL (project VA317P18), the CIBER-BBN, the JCyL and the Instituto de Salud Carlos III under the “Network Center of Regenerative Medicine and Cellular Therapy of Castilla and Leon”.Peer reviewedAmerican Chemical SocietyEuropean CommissionMinisterio de Ciencia, Innovación y Universidades (España)Comunidad de MadridJunta de Castilla y LeónInstituto de Salud Carlos IIICentro en Red de Medicina regenerativa y Terapia celular de Castilla y LeónGonzalez-Valdivieso, Juan [0000-0001-9007-2312]Borrego, Belén [0000-0002-0801-9166]Girotti, Alessandra [0000-0003-4754-7022]Moreno, Sandra [0000-0002-3548-037X]Brun Torres, Alejandro [0000-0001-7865-538X]Bermejo-Martin, Jesús [0000-0002-7998-6268]Arias, F. Javier [0000-0001-8584-3768]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202320232020info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Postprintinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttp://hdl.handle.net/10261/340799https://api.elsevier.com/content/abstract/scopus_id/85084699015reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/EC/H2020/646075info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/DTS19%2F00162info:eu-repo/grantAgreement/MICIUN//MAT2016-79435-Rinfo:eu-repo/grantAgreement/MICIUN//AGL2017-82336-Rinfo:eu-repo/grantAgreement/MICIUN//MAT2016-78903-RS2018/BAA-4370Centro de Investigación en Sanidad Animal (CISA)https://doi.org/10.1021/acs.molpharmaceut.0c00054Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3407992026-05-22T06:33:51Z
dc.title.none.fl_str_mv A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus
title A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus
spellingShingle A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus
Gonzalez-Valdivieso, Juan
DNA vaccines
Rift Valley fever virus
Elastin-like recombinamers (ELRs)
In vivo immunogenicity
Vaccine technologies
title_short A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus
title_full A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus
title_fullStr A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus
title_full_unstemmed A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus
title_sort A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus
dc.creator.none.fl_str_mv Gonzalez-Valdivieso, Juan
Borrego, Belén
Girotti, Alessandra
Moreno, Sandra
Brun Torres, Alejandro
Bermejo-Martin, Jesús
Arias, F. Javier
author Gonzalez-Valdivieso, Juan
author_facet Gonzalez-Valdivieso, Juan
Borrego, Belén
Girotti, Alessandra
Moreno, Sandra
Brun Torres, Alejandro
Bermejo-Martin, Jesús
Arias, F. Javier
author_role author
author2 Borrego, Belén
Girotti, Alessandra
Moreno, Sandra
Brun Torres, Alejandro
Bermejo-Martin, Jesús
Arias, F. Javier
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv European Commission
Ministerio de Ciencia, Innovación y Universidades (España)
Comunidad de Madrid
Junta de Castilla y León
Instituto de Salud Carlos III
Centro en Red de Medicina regenerativa y Terapia celular de Castilla y León
Gonzalez-Valdivieso, Juan [0000-0001-9007-2312]
Borrego, Belén [0000-0002-0801-9166]
Girotti, Alessandra [0000-0003-4754-7022]
Moreno, Sandra [0000-0002-3548-037X]
Brun Torres, Alejandro [0000-0001-7865-538X]
Bermejo-Martin, Jesús [0000-0002-7998-6268]
Arias, F. Javier [0000-0001-8584-3768]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv DNA vaccines
Rift Valley fever virus
Elastin-like recombinamers (ELRs)
In vivo immunogenicity
Vaccine technologies
topic DNA vaccines
Rift Valley fever virus
Elastin-like recombinamers (ELRs)
In vivo immunogenicity
Vaccine technologies
description 13 Pág.
publishDate 2020
dc.date.none.fl_str_mv 2020
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Postprint
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/340799
https://api.elsevier.com/content/abstract/scopus_id/85084699015
url http://hdl.handle.net/10261/340799
https://api.elsevier.com/content/abstract/scopus_id/85084699015
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/EC/H2020/646075
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/DTS19%2F00162
info:eu-repo/grantAgreement/MICIUN//MAT2016-79435-R
info:eu-repo/grantAgreement/MICIUN//AGL2017-82336-R
info:eu-repo/grantAgreement/MICIUN//MAT2016-78903-R
S2018/BAA-4370
Centro de Investigación en Sanidad Animal (CISA)
https://doi.org/10.1021/acs.molpharmaceut.0c00054
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv American Chemical Society
publisher.none.fl_str_mv American Chemical Society
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418834089213952
score 15,812429

Similares en LA Referencia